Ippocastano proprietà terapeutiche

[Royalsapphire]

Impiego principale: nell'insufficienza venosa (contro le varici)
Altri impieghi: emorroidi (che sono di fatto una forma di vene varicose), flebiti, varicocele (vene varicose dei testicoli), lesioni minori (contusioni, lesioni alle articolazioni e ai legamenti; Lesioni muscolari, strappi e stiramenti; Lesioni sportive come infortuni minori, distorsioni e tensioni).

In Germania e' il terzo fitoterapico più venduto dopo Ginkgo e Erba di San Giovanni (Iperico).
In Giappone è largamente utilizzato in formulazioni iniettabili dopo interventi chirurgici e ferite.

L'attività principale è dovuta al principio attivo che è una saponina nota come Escina, la quale combatte gonfiore e infiammazione, e inibisce anche il rilascio di enzimi glicosaminoglicani idrolasi, i quali tagliano le fibre di collagene, costituente principale della parete capillare (cosi si riduce gonfiore e infiammazione).

L'Ippocastano, insieme alle calze a compressione graduata è il trattamento standard per prevenire e trattare le vene varicose e la gambe gonfie e pesanti, in quanto è stato dimostrato che riduce dolore e gonfiore.

DOSAGGIO INTERNO PER EMORROIDI
50 mg di Escina 3 volte al giorno. Cosi facendo si registrano miglioramenti nel dolore, sanguinamento e gonfiore entro 1 settimana; entro 2 settimane, i benefici sono visibili mediante esame obiettivo.

DOSAGGIO ESTERNO PER CONTUSIONI (LIVIDI ED EMATOMI) E GAMBE GONFIE
Applicare sul livido/contusione 10 g di gel al 2% di Escina, in una dose singola giornaliera.

DOSAGGIO PER TRATTAMENTO INTERNO

Dosaggio
Il più comune è di 300 mg due volte al giorno, standardizzato per contenere 50 mg di escina pro dose, per una dose giornaliera totale di 100 mg di escina.

I preparati di ippocastano dovrebbero certificare che un componente tossico chiamato esculina è stato rimosso (vedere Problemi di sicurezza).
Inoltre, una formulazione a rilascio ritardato può essere utilizzata per prevenire disordini gastrointestinali.


References[ - ]

1. Newall C, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals. London, England: Pharmaceutical Press; 1996:166.

2. Kreysel HW, Nissen HP, Enghoffer E. A possible role of lysosomal enzymes in the pathogenesis of varicosis and the reduction in their serum activity by Venostatin. Vasa. 1983;12:377-382.

3. Bougelet C, Roland IH, Ninane N, et al. Effect of aescine on hypoxia-induced neutrophil adherence to umbilical vein endothelium. Eur J Pharmacol. 1998;345:89-95.

4. Wilhelm K, Feldmeier C. Thermometric investigations about the efficacy of beta-escin to reduce postoperative edema [in German; English abstract]. Med Klin. 1977;72:128-134.

5. Calabrese C, Preston P. Report of the results of a double-blind, randomized, single-dose trial of a topical 2% escin gel versus placebo in the acute treatment of experimentally-induced hematoma in volunteers. Planta Med. 1993;59:394-397.

6. Friederich HC, Vogelsberg H, Neiss A. Evaluation of internally effective venous drugs [translated from German]. Z Hautkr. 1978;53:369-374.

7. Neiss A, Bohm C. Demonstration of the effectiveness of the horse-chestnut-seed extract in the varicose syndrome complex [translated from German]. MMW Munch Med Wochenschr. 1976;118:213-216.

8. Bisler H, Pfeifer R, Kluken N, et al. Effects of horse-chestnut seed extract on transcapillary filtration in chronic venous insufficiency [translated from German]. Dtsch Med Wochenschr. 1986;111:1321-1329.

9. Lohr E, Garanin G, Jesau P, et al. Anti-edemic therapy in chronic venous insufficiency with tendency to formation of edema [translated from German]. Munch Med Wochenschr. 1986;128:579-581.

10. Rudofsky G, Neiss A, Otto K, et al. Antiedematous effects and clinical effectiveness of horse chestnut seed extract in double blind studies [translated from German]. Phlebologie und Proktologie. 1986;15:47-54.

11. Steiner M, Hillemanns HG. Investigation of the anti-edemic efficacy of VenostatinŴ [translated from German]. Munch Med Wochenschr. 1986;128:551-552.

12. Alter H. Medication therapy for varicosis [translated from German]. Z Allgemeinmed. 1973;49:1301-1304.

13. Diehm C, Trampisch HJ, Lange S, et al. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet. 1996;347:292-294.

14. Pittler MH, Ernst E. Horse-chestnut seed extract for chronic venous insufficiency. A criteria-based systematic review. Arch Dermatol. 1998;134:1356-1360.

15. Neiss A, Bohm C. Demonstration of the effectiveness of the horse-chestnut-seed extract in the varicose syndrome complex [translated from German]. MMW Munch Med Wochenschr. 1976;118:213-216.

16. Lohr E, Garanin G, Jesau P, et al. Anti-edemic therapy in chronic venous insufficiency with tendency to formation of edema [translated from German]. Munch Med Wochenschr. 1986;128:579-581.

17. Diehm C, Trampisch HJ, Lange S, et al. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet. 1996;347:292-294.

18. Calabrese C and Preston P. Report of the results of a double-blind, randomized, single-dose trial of a topical 2% escin gel versus placebo in the acute treatment of experimentally-induced hematoma in volunteers. Planta Med. 1993;59:394-397.

19. Chandler RF. Horse chestnut. Can Pharm J. 1993;126:297-300, 306.

20. Diehm C. The role of oedema protective drugs in the treatment of chronic venous insufficiency: a review of evidence based on placebo-controlled clinical trials with regard to efficacy and tolerance. Phlebology. 1996;11:23-29.

21. Hitzenberger G. The therapeutic effectiveness of chestnut extract [translated from German]. Wien Med Wochenschr. 1989;139:385-389.

22. Schulz V, Hansel R, Tyler VE. Rational Phytotherapy: A Physicians' Guide to Herbal Medicine. 3rd ed. Berlin, Germany: Springer-Verlag; 1998:131.

23. Grasso A, Corvaglia E. Two cases of suspected toxic tubulonephrosis due to Escine [in Italian;English abstract]. Gazz Med It. 1976;135:581-584.

24. Reynolds JF, ed. Martindale, the Extra Pharmacopeia. London, England: Pharmaceutical Press; 1989:1539-1540.

25. Rothkopf M, Vogel G, Lang W, et al. Animal experiments on the question of the renal toleration of the horse chestnut saponin aescin. Arzneimittelforschung. 1977;27:598-605.

26. Takegoshi K, Tohyama T, Okuda K, et al. A case of Venoplant-induced hepatic injury. Gastroenterol Jpn. 1986;21:62-65.

27. Brinker F. Herb Contraindications and Drug Interactions: With Appendices Addressing Specific Conditions and Medicines. 2nd ed. Sandy, Ore: Eclectic Medical Publications; 1998:84.

28. Brooks S. Botanical Toxicology. Protocol J Bot Med. 1995;1:147-158.

29. Schulz V, Hansel R, Tyler VE. Rational Phytotherapy: A Physicians' Guide to Herbal Medicine. 3rd ed. Berlin, Germany: Springer-Verlag; 1998:132.

30. Koch R. Comparative study of Venostasin and Pycnogenol in chronic venous insufficiency. Phytother Res. 2002;16(Suppl 1):S1-S5.

31. Sirtori CR. Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res. 2001;44:183-193.

32. Pittler M, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev. 2010;(9):CD003230.

33. Fang Y, Zhao L, Yan F, Xia X, Xu D, Cui X. Escin improves sperm quality in male patients with varicocele-associated infertility. Phytomedicine. 2010;17(3-4):192-196.